Lilly's oral GLP-1 orforglipron shows effectiveness in reducing A1C levels in adults with diabetes

From Nasdaq: 2025-06-22 13:29:00

Eli Lilly And Co.’s oral GLP-1 receptor agonist, orforglipron, showed significant efficacy in reducing A1C levels in adults with type 2 diabetes, with an average weight loss of 16.0 pounds at the highest dose. The Phase 3 trial, ACHIEVE-1, demonstrated superior A1C reduction across all three doses (3 mg, 12 mg, 36 mg) of orforglipron, with positive results in key secondary endpoints. Lilly plans to share more results later this year and aims to submit orforglipron for weight management by the end of 2021 and for the treatment of type 2 diabetes in 2026.



Read more at Nasdaq: Lilly’s Oral GLP-1 Orforglipron Demonstrates Efficacy In Type 2 Diabetes Treatment In Phase 3 Trial